Dexanabinol

Drug Profile

Dexanabinol

Alternative Names: Dexanabinone; ETS-2101; HU-211; PA-50211; PRS-211007; Sinnabidol

Latest Information Update: 07 Apr 2016

Price : $50

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer e-Therapeutics; Northern Institute for Cancer Research; Pharmos Corporation; University of California, San Diego
  • Class 3-ring heterocyclic compounds; Antineoplastics; Cannabinoids; Neuroprotectants; Small molecules
  • Mechanism of Action Apoptosis stimulants; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Brain cancer; Solid tumours
  • Preclinical Malignant melanoma
  • Discontinued Brain injuries; Glaucoma; Mild cognitive impairment; Multiple sclerosis

Most Recent Events

  • 22 Mar 2016 e-Therapeutics completes a phase-I trial in Solid tumours in Poland, United Kingdom, Spain and Germany (IV) (NCT02423239) prior to March 2016
  • 22 Mar 2016 e-Therapeutics completes a phase Ia trial for Brain cancer (Second-line therapy or greater) in USA (NCT01654497) prior to March 2016
  • 01 Jul 2015 e-Therapeutics completes a phase I trial for Solid tumours (Second-line therapy or greater, Late-stage disease) in the United Kingdom (NCT01489826)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top